MTOR and breast cancer: In this study, we focus on the downstream mTOR effectors S6K1, S6K2 and 4EBP1 that have been shown amplified and overexpressed in breast cancer and associated with an adverse prognosis, and also implicated as markers of outcome after endocrine treatment.